首页> 外文期刊>Blood: The Journal of the American Society of Hematology >A Multi-Institutional Outcomes Analysis of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Ibrutinib

【24h】

A Multi-Institutional Outcomes Analysis of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Ibrutinib

机译：依鲁替尼治疗复发或难治性弥漫性大B细胞淋巴瘤的多机构结果分析

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Blood: The Journal of the American Society of Hematology》 |2016年第22期|共5页
作者
Winter Allison Marie; Landsburg Daniel J.; Hernandez-Ilizaliturri Francisco J.; Reddy Nishitha; Smith Stephen; Shadman Mazyar; Caimi Paolo; Jagadeesh Deepa; Smith Mitchell R.; Hill Brian T.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. A Multi-Institutional Outcomes Analysis of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Ibrutinib [J] . Winter Allison Marie, Landsburg Daniel J., Hernandez-Ilizaliturri Francisco J., Blood: The Journal of the American Society of Hematology . 2016,第22期

机译：依鲁替尼治疗复发或难治性弥漫性大B细胞淋巴瘤的多机构结果分析
2. UGT1A1*6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan [J] . Yamasaki Satoshi, Tanimoto Kazuki, Kohno Kentarou, Annals of hematology . 2015,第1期

机译：UGT1A1 * 6基因多态性可预测卡铂，地塞米松，依托泊苷和伊立替康治疗的复发性或难治性弥漫性大B细胞淋巴瘤的老年患者的预后
3. Pretreatment prognostic factors and outcome in patients with relapsed or primary-refractory diffuse large B-cell lymphoma treated with second-line chemotherapy and autologous stem cell transplantation. [J] . Moskowitz CH Annals of oncology: official journal of the European Society for Medical Oncology . 2006,第Suppla4期

机译：二线化疗和自体干细胞移植治疗复发或原发难治性弥漫性大B细胞淋巴瘤的患者的治疗前预后因素和结果。
4. Mutational profile of Diffuse Large B-cell Lymphoma with central nervous system relapse: analysis of CBioPortal for Cancer Genomics database [C] . Elena Voropaeva, Olga Beresina, Tatyana Pospelova, Conference on Cognitive Sciences, Genomics and Bioinformatics . 2020

机译：弥漫性大B细胞淋巴瘤与中枢神经系统复发的突变特征：用于癌症基因组学数据库的CBioPortal分析
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy [O] . Daniel J. Landsburg, Mitchell E. Hughes, Alexa Koike, 2019

机译：依鲁替尼单药治疗复发/难治性双表达B细胞淋巴瘤患者的结果
7. Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy [O] . Daniel J. Landsburg, Mitchell E. Hughes, Alexa Koike, 2019

机译：用Ibrutinib单疗法治疗复发/难治性双胸B细胞淋巴瘤患者的结果

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号